Kristian Stengaard-Pedersen

Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis. / Laustsen, Julie K.; Rasmussen, Tue K.; Stengaard-Pedersen, Kristian; Hørslev-Petersen, Kim; Hetland, Merete L.; Østergaard, Mikkel; Junker, Peter; Hvid, Malene; Deleuran, Bent.

In: Arthritis Research and Therapy, Vol. 16, No. 1, 474, 30.10.2014.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Laustsen, JK, Rasmussen, TK, Stengaard-Pedersen, K, Hørslev-Petersen, K, Hetland, ML, Østergaard, M, Junker, P, Hvid, M & Deleuran, B 2014, 'Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis', Arthritis Research and Therapy, vol. 16, no. 1, 474. https://doi.org/10.1186/s13075-014-0474-4

APA

Laustsen, J. K., Rasmussen, T. K., Stengaard-Pedersen, K., Hørslev-Petersen, K., Hetland, M. L., Østergaard, M., ... Deleuran, B. (2014). Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis. Arthritis Research and Therapy, 16(1), [474]. https://doi.org/10.1186/s13075-014-0474-4

CBE

Laustsen JK, Rasmussen TK, Stengaard-Pedersen K, Hørslev-Petersen K, Hetland ML, Østergaard M, Junker P, Hvid M, Deleuran B. 2014. Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis. Arthritis Research and Therapy. 16(1). https://doi.org/10.1186/s13075-014-0474-4

MLA

Vancouver

Laustsen JK, Rasmussen TK, Stengaard-Pedersen K, Hørslev-Petersen K, Hetland ML, Østergaard M et al. Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis. Arthritis Research and Therapy. 2014 Oct 30;16(1). 474. https://doi.org/10.1186/s13075-014-0474-4

Author

Laustsen, Julie K. ; Rasmussen, Tue K. ; Stengaard-Pedersen, Kristian ; Hørslev-Petersen, Kim ; Hetland, Merete L. ; Østergaard, Mikkel ; Junker, Peter ; Hvid, Malene ; Deleuran, Bent. / Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis. In: Arthritis Research and Therapy. 2014 ; Vol. 16, No. 1.

Bibtex

@article{232e58d4228540cd80eeefdb7b77c7e7,
title = "Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis",
abstract = "Introduction: OX40 and its ligand OX40L are key components in the generation of adaptive memory response and provide necessary co-stimulatory signals for activated effector T cells. Here we investigate the dual roles of the membrane and soluble (s) forms of OX40 and OX40L in plasma and synovial fluid and their association with autoantibodies and disease activity in rheumatoid arthritis (RA). Methods: Soluble OX40 and sOX40L plasma levels were measured in treatment-na{\"i}ve early RA patients (eRA) at baseline and after 3, 6, and 12 months of treatment with methotrexate and adalimumab (n = 39) and with methotrexate alone (n = 37). Adalimumab was discontinued after the first year, and patients were followed for additional 12 months. For comparison, sOX40 and sOX40L were measured in patients with chronic RA (cRA, n = 15) and healthy volunteers (HV, n = 34). Membrane-bound OX40 and OX40L expression on T cells, B cells and monocytes were quantified. Results: Soluble OX40 plasma levels of eRA patients were not different at the time of treatment initiation, but were significantly higher after 12 months of treatment, compared with HV or cRA patients. Soluble OX40L was significantly elevated throughout the first 12 months of treatment compared with HVs and patients with cRA. Adalimumab treatment did not influence sOX40 or sOX40L plasma levels. At baseline, sOX40L levels were strongly associated with the presence of anti-citrullinated protein antibodies (ACPA) (P < 0.001) and IgM-RF (P < 0.0001). The sOX40/sOX40L ratio was decreased in eRA, and a low ratio at the time of adalimumab discontinuation was associated with increased DAS28CRP and risk of flare the following year. T cells in the synovial fluid had the highest expression of OX40, while monocytes and B cells were the main expressers of OX40L in the joint. Conclusions: Plasma levels of sOX40 and sOX40L were increased in eRA and sOX40L was correlated with ACPA and IgM-RF. Further, expression of membrane-bound OX40 and OX40L was increased in eRA and cRA. Combined, these findings could reflect that increased activity in the OX40 systems facilitate to drive disease activity and autoantibody production in RA.",
author = "Laustsen, {Julie K.} and Rasmussen, {Tue K.} and Kristian Stengaard-Pedersen and Kim H{\o}rslev-Petersen and Hetland, {Merete L.} and Mikkel {\O}stergaard and Peter Junker and Malene Hvid and Bent Deleuran",
year = "2014",
month = "10",
day = "30",
doi = "10.1186/s13075-014-0474-4",
language = "English",
volume = "16",
journal = "Arthritis Research & Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "1",

}

RIS

TY - JOUR

T1 - Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis

AU - Laustsen, Julie K.

AU - Rasmussen, Tue K.

AU - Stengaard-Pedersen, Kristian

AU - Hørslev-Petersen, Kim

AU - Hetland, Merete L.

AU - Østergaard, Mikkel

AU - Junker, Peter

AU - Hvid, Malene

AU - Deleuran, Bent

PY - 2014/10/30

Y1 - 2014/10/30

N2 - Introduction: OX40 and its ligand OX40L are key components in the generation of adaptive memory response and provide necessary co-stimulatory signals for activated effector T cells. Here we investigate the dual roles of the membrane and soluble (s) forms of OX40 and OX40L in plasma and synovial fluid and their association with autoantibodies and disease activity in rheumatoid arthritis (RA). Methods: Soluble OX40 and sOX40L plasma levels were measured in treatment-naïve early RA patients (eRA) at baseline and after 3, 6, and 12 months of treatment with methotrexate and adalimumab (n = 39) and with methotrexate alone (n = 37). Adalimumab was discontinued after the first year, and patients were followed for additional 12 months. For comparison, sOX40 and sOX40L were measured in patients with chronic RA (cRA, n = 15) and healthy volunteers (HV, n = 34). Membrane-bound OX40 and OX40L expression on T cells, B cells and monocytes were quantified. Results: Soluble OX40 plasma levels of eRA patients were not different at the time of treatment initiation, but were significantly higher after 12 months of treatment, compared with HV or cRA patients. Soluble OX40L was significantly elevated throughout the first 12 months of treatment compared with HVs and patients with cRA. Adalimumab treatment did not influence sOX40 or sOX40L plasma levels. At baseline, sOX40L levels were strongly associated with the presence of anti-citrullinated protein antibodies (ACPA) (P < 0.001) and IgM-RF (P < 0.0001). The sOX40/sOX40L ratio was decreased in eRA, and a low ratio at the time of adalimumab discontinuation was associated with increased DAS28CRP and risk of flare the following year. T cells in the synovial fluid had the highest expression of OX40, while monocytes and B cells were the main expressers of OX40L in the joint. Conclusions: Plasma levels of sOX40 and sOX40L were increased in eRA and sOX40L was correlated with ACPA and IgM-RF. Further, expression of membrane-bound OX40 and OX40L was increased in eRA and cRA. Combined, these findings could reflect that increased activity in the OX40 systems facilitate to drive disease activity and autoantibody production in RA.

AB - Introduction: OX40 and its ligand OX40L are key components in the generation of adaptive memory response and provide necessary co-stimulatory signals for activated effector T cells. Here we investigate the dual roles of the membrane and soluble (s) forms of OX40 and OX40L in plasma and synovial fluid and their association with autoantibodies and disease activity in rheumatoid arthritis (RA). Methods: Soluble OX40 and sOX40L plasma levels were measured in treatment-naïve early RA patients (eRA) at baseline and after 3, 6, and 12 months of treatment with methotrexate and adalimumab (n = 39) and with methotrexate alone (n = 37). Adalimumab was discontinued after the first year, and patients were followed for additional 12 months. For comparison, sOX40 and sOX40L were measured in patients with chronic RA (cRA, n = 15) and healthy volunteers (HV, n = 34). Membrane-bound OX40 and OX40L expression on T cells, B cells and monocytes were quantified. Results: Soluble OX40 plasma levels of eRA patients were not different at the time of treatment initiation, but were significantly higher after 12 months of treatment, compared with HV or cRA patients. Soluble OX40L was significantly elevated throughout the first 12 months of treatment compared with HVs and patients with cRA. Adalimumab treatment did not influence sOX40 or sOX40L plasma levels. At baseline, sOX40L levels were strongly associated with the presence of anti-citrullinated protein antibodies (ACPA) (P < 0.001) and IgM-RF (P < 0.0001). The sOX40/sOX40L ratio was decreased in eRA, and a low ratio at the time of adalimumab discontinuation was associated with increased DAS28CRP and risk of flare the following year. T cells in the synovial fluid had the highest expression of OX40, while monocytes and B cells were the main expressers of OX40L in the joint. Conclusions: Plasma levels of sOX40 and sOX40L were increased in eRA and sOX40L was correlated with ACPA and IgM-RF. Further, expression of membrane-bound OX40 and OX40L was increased in eRA and cRA. Combined, these findings could reflect that increased activity in the OX40 systems facilitate to drive disease activity and autoantibody production in RA.

UR - http://www.scopus.com/inward/record.url?scp=84990876677&partnerID=8YFLogxK

U2 - 10.1186/s13075-014-0474-4

DO - 10.1186/s13075-014-0474-4

M3 - Journal article

C2 - 25359291

AN - SCOPUS:84990876677

VL - 16

JO - Arthritis Research & Therapy

JF - Arthritis Research & Therapy

SN - 1478-6354

IS - 1

M1 - 474

ER -